On May 11, 2026, Paul A. LaViolette, CEO of Pulse Biosciences (PLSE), made a significant move by purchasing 15,000 shares of the company’s stock at $19.69 each, as reported in a SEC Form 4 filing. This transaction increased his direct ownership from 846 to 15,846 shares, marking a dramatic 1,773% rise in his stake, now representing approximately 0.02% of outstanding shares.
LaViolette’s purchase comes at a pivotal time for Pulse Biosciences, which recently announced a strategic shift towards its nPulse Cardiac Catheter System following promising clinical trial results. The stock has since surged to a 52-week high of $27.98, reflecting a 24.7% gain from the purchase price. However, the company is still in the early stages of revenue generation, with only $401,000 in sales and a net loss of $18.6 million in Q1.
This transaction signals LaViolette’s strong belief in the company’s future, suggesting that he anticipates positive developments ahead, which could further influence investor sentiment and stock performance.
Source: fool.com